Prognostic value of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) in patients with RAS-mutant metastatic colorectal cancer.

ABSTRACT:

Background

Patients with metastatic colorectal cancer (mCRC) generally have a poor prognosis, and treatment strategies are highly dependent on the RAS mutational status. During disease progression, patients often exhibit dynamic changes in serum lipid profiles. However, the prognostic significance of cholesterol-related biomarkers remains controversial. This study aimed to investigate the association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and clinical outcomes in patients with RAS-mutant mCRC.

Methods

This retrospective study included 287 RAS-mutant mCRC patients, all of whom received at least three cycles of chemotherapy combined with bevacizumab. Among them, 169 patients were assigned to the training cohort

SUBMITTER: Xie W 

PROVIDER: S-EPMC12617302 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature